Safety & Efficacy of the J-Valve Ausper System in Patients With Severe Aortic Stenosis and/or Aortic Regurgitation
Aortic Valve Disease
About this trial
This is an interventional treatment trial for Aortic Valve Disease focused on measuring Severe Aortic Stenosis and/or severe aortic regurgitation
Eligibility Criteria
Inclusion Criteria:
- Signed Informed Consent
- Age ≥18years of age
- Presents with symptomatic aortic stenosis and/or aortic regurgitation, as well as NYHA rating of NYHA ≥ II
- Has undergone the diagnosis of at least one interventional cardiologist and two cardiac surgeons: the patients are contraindicated for traditional open heart valve replacement surgery (defined as 30 days post-op mortality risk >50%, irreversible complications, or other influential post-operative factors [such as severe calcification in the ascending aorta and aortic valve, weak physical condition, chest deformities, severe liver diseases, severe lung diseases, etc.] or high risk for surgery (LogEuroSCORE≥20% and or STS≥8)
- Has a diagnosis from at least one interventional cardiologist and two cardiac surgeons that the patient may benefit from a valve implantation
- Severe aortic stenosis with electrocardiography results as follows: mean transvalvular pressure gradient ≥40 mmHg or maximal forward aortic blood flow velocity of ≥4.0 m/s, aortic valve area < 0.8 cm2 (or AVA index < 0.5 cm2/m2); and/or severe aortic regurgitation, electrocardiography results show symptomatic moderate regurgitation or severe regurgitation
- Without severe pulmonary arterial hypertension
The patient is willing to cooperate with all follow-up visits.
Anatomical Inclusion Criteria:
- Aortic annulus >19mm and <29mm, standardized using cardiac CT measurements;
- Ascending aortic diameter <50mm at the sinotubular junction.
Exclusion Criteria:
- Patients with infection or who have any sign of infection
- Previous history of endocarditis or patients with active endocarditis
- Incidence of acute myocardial infarction within the past 30 days (Q-wave MI, or non Q-wave MI with creatine kinase, an increase in troponin T)
- Any cardiac mass discovered during echocardiography, left ventricular or atrial thrombosis
- Suffering from uncontrollable atrial fibrillation
- Hereditary hypertrophic cardiomyopathy
- Mitral or tricuspid valve insufficiency (Class Ⅱ regurgitation or greater)
- Has previously undergone aortic valve implantation (mechanical valve or biological valve frame)
- Is known to be allergic to contrast agents, aspirin, heparin, ticlopidine medications, nitinol or porcine products
- Is known to be contraindicated for or is allergic to all anti-coagulants or is unable to use anti-coagulants during the study
Is known to have one of the following conditions (according to evaluations beginning from screening through the day of the procedure):
- Other diseases that may reduce the life expectancy to less than 12 months (such as clinically recurrent or metastatic cancer, congestive heart failure, etc.)
- Currently has drug abuse problems (such as alcohol, cocaine, heroin, etc.)
- Plans to undergo surgery that may result in non-compliance with the study protocol or that may cause confusion in data interpretation.
- Has experienced a cerebrovascular accident (CVA) within the last 6 months
- Patients suffering from stenosis of the carotid, internal carotid, or vertebral arteries (70%)
- White cell count <3×109/L, platelet count<50×109/L
- Hemoglobin <90 g/L
- Severely lowered left ventricular function, left ventricular ejection fraction < 20 %
- Aortic aneurysm in the abdomen or chest
- Hepatic encephalopathy or acute active hepatitis
- Currently undergoing dialysis or baseline creatine levels >2.5 mg/dL (221μmoI/L)
- Prone to bleeding, has a history of clotting disorders or refuses blood transfusions
- Active ulcer or active gastrointestinal (GI) bleeding
- Suffering from nervous system diseases that severely influence the patients' ability to move or to perform daily activities
- Patients with severe dementia
- Any reason for emergent surgery
- Taking part in other clinical trials for pharmaceuticals or medical devices
Those who are pregnant, plan to become pregnant, or who are taking estrogen or estrogen-like drugs (women suspected of being pregnant must test negative on a urine pregnancy test or for chorionic gonadotropin serum).
-
Sites / Locations
- West China Hospital
- Zhongshan Hospital
- Fuwai Cardiovascular Hospital
Arms of the Study
Arm 1
Other
Single arm observational study
Intervention: J-Valve Transcatheter Aortic valve replacement. Prospective, multi-center, single arm observational study. Subjects will include patients with severe aortic valve stenosis and/or severe aortic regurgitation who require replacement of their native aortic valve.